yu foundation top banner

Introduction:

This is a third-party research done by a grant from YuFoundation for Tom Seyfried to research Dr. Young Ko’s 3 Bromopyruvate antimetabolic drug used in cancers. The important outcome is when 3 BP was injected into the primary cancer site, the metastatic rate was impressively low. Therefore, spread of the cancers may be hindered with this molecule. Please read more in section under grants and scientific information.


Progress Report

Therapeutic efficacy of 3-bromopyruvate when Injected intratumorally on the growth of VM-M3 and CT-2A brain tumor cells


Thomas N. Seyfried
Boston College
April 24, 2017

metastasis 3bpThe previous progress reports showed that 3-BP was unable to produce a therapeutic effect against the VM-M3 tumor grown in its syngeneic VM/Dk mouse host. We suggested that this might be due to:

  1. The greater dependence of the VM-M3 tumor on glutaminolysis than on glycolysis for energy production.
  2. The low bioavailability of 3-BP after IP injection.

The glycolytic phenotype of the CT-2A glioma tumor makes this an attractive tumor model for studying 3-BP. Also, we will inject 3-BP directly into the VM-M3 and CT-2A tumors grown subcutaneously in flank.

Progress Report

This is a third-party research done by a grant from YuFoundation for Tom Seyfried to research Dr.Young Ko’s 3 Bromopyruvate antimetabolic drug used in cancers. The important outcome is when 3 BP was injected into the primary cancer site, the metastatic rate was impressively low. Therefore, spread of the cancers may be hindered with this molecule. Please read more in section under grants and scientific information.

yu report thumb


Tripping Over The Truth Seminars & Discussion Videos

Subscribe now to watch over 100 hours of the leading scientists and doctors discussing their research.


yu ttot sidebar



playbutton

Watch video of Nuclear Transfer Studies of Cancer Cells



No more than 10% of our donations go to general expense. 90% must go to research.

 

We Need Your Pre-Tax Donations!

Read More...

Share!